Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $10.57.

AQST has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Monday. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th.

Aquestive Therapeutics Stock Up 11.4 %

Aquestive Therapeutics stock opened at $2.94 on Thursday. Aquestive Therapeutics has a 52-week low of $2.24 and a 52-week high of $6.23. The firm has a fifty day moving average of $3.04 and a 200-day moving average of $4.07. The firm has a market capitalization of $290.68 million, a P/E ratio of -6.53 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. On average, research analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AQST. New York State Common Retirement Fund boosted its stake in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after acquiring an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $44,000. Two Sigma Advisers LP acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $57,000. PKS Advisory Services LLC acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $63,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $69,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.